The world's first bivalent mRNA vaccine candidate against respiratory syncytial virus, or RSV, kicked off Phase I clinical ...

Australia’s audit office will probe the Morrison government’s $2 billion deal with US pharmaceutical giant Moderna to set up ...

Brad Miller, Moderna's CIO, has driven technology innovation to help drive continued gains for the roughly $7 billion revenue ...

The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory ...

There is no evidence Japan has named the COVID-19 vaccine the “most deadly drug in history,” as the post claims.

They found that mRNA vaccines that target C. diff cells and the toxins they produce generated a lasting immune response in ...

With the possibility of Robert F. Kennedy, Jr. being involved in health policy in the next administration, vaccination – especially mRNA vaccines – will become a hot topic. Is there anything to fear ...

Welcome to the Moderna third quarter 2024 conference call. [Operator instructions] Please be advised today's conference is ...

With a test currently under FDA review, Inflammatix commences a 600 patient-strong clinical trial in emergency departments.

Moderna (MRNA) stock gains as company posts better than expected Q3 results driven by its updated COVID-19 vaccine. Read more ...

The company says it expects the RSV vaccine — called mRESVIA — to be available in early 2025. There are two other vaccines ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...